Insulet Corporation (ETR:GOV)

Market Cap	9.57B -49.0%
Revenue (ttm)	2.52B +31.9%
Net Income	262.62M -24.7%
EPS	3.72 -22.7%
Shares Out	n/a
PE Ratio	36.43
Forward PE	23.32
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1
Open	144.55
Previous Close	139.20
Day's Range	144.55 - 144.55
52-Week Range	123.80 - 144.55
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 5, 2026

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controll...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 2000
• Employees: 5,400
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: GOV

Financial Performance

In 2025, Insulet's revenue was $2.71 billion, an increase of 30.73% compared to the previous year's $2.07 billion. Earnings were $247.10 million, a decrease of -40.93%.

Financial numbers in USD

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 10, 2026

Data Sources Report a data error